CBChristine Bouchardy

Christine Bouchardy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christine Bouchardy has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2015
      • Vol. 36  (5) , 529-32

    Stage IVB endometrial cancer: clinical course and survival of patients with single and multiple metastases.

    by O Kraemer, E Rapiti, D Huber, E Lopes-Raimundo, M Usel, C Bouchardy, P Petignat

    Metastatic endometrial cancer (EC) at initial presentation is a rare disease. The present aim was to evaluate prognostic factors and overall survival in patients diagnosed with metastatic EC. Using data from the Geneva Cancer Registry, the authors included all patients diagnosed with Stage IVB EC from 1980-2007. Estimates of survival were calculated using the Kaplan-Meier method and compared using the log-rank test. A total of 38 patients were identified. The most frequent metastases were peritoneal or pleural carcinomatosis (66%, n=25) and hematogenous metastases (53%, n=20). Five-year survival rate was 5.7% (95% confidence interval: 0.0-13.3), and median survival was 7.6 months. Survival of patients with a single metastasis at the time of diagnosis was longer than for patients with multiple metastases (16 versus two months, respectively; p < 0.00 1). Metastatic EC is rare disease with very poor prognosis particularly for patients with multiple site metastases.


  • Breast cancer management and outcome according to surgeon's affiliation: a population-based comparison adjusted for patient's selection bias

    by F. Taban, E. Rapiti, G. Fioretta, Y. Wespi, D. Weintraub, A. Hugli, H. Schubert, G. Vlastos, M. Castiglione, C. Bouchardy

    Studies have reported that breast cancer (BC) units could increase the quality of care but none has evaluated the efficacy of alternative options such as private BC networks, which is our study objective. We included all 1404 BC patients operated in the public unit or the private network and recorded at the Geneva Cancer Registry between 2000 and 2005. We compared quality indicators of care between the public BC unit and the private BC network by logistic regression and evaluated the effect of surgeon's affiliation on BC-specific mortality by the Cox model adjusting for the propensity score. Both the groups had high care quality scores. For invasive cancer, histological assessment before surgery and axillary lymph node dissection when indicated were less frequent in the public sector (adjusted odds ratio (OR): 0.4, 95% confidence interval (CI) 0.3-0.7, and OR: 0.4, 95% CI 0.2-0.8, respectively), while radiation therapy after breast-conserving surgery was more frequent (OR: 2.5, 95% CI 1.4-4.8). Surgeon affiliation had no substantial effect on BC-specific mortality (adjusted hazard ratio (HR): 0.8, 95% CI 0.5-1.4). This study suggests that private BC networks could be an alternative to public BC units with both structures presenting high quality indicators of BC care and similar BC-specific mortality.


  • 3505 POSTER Anti-oestrogen Therapy for Breast Cancer Modifies the Risk of Subsequent Cutaneous Melanoma

    by C. Huber, C. Bouchardy, R. Schaffar, I. Neyroud-Caspar, E. Rapiti, G. Vlastos, F.A. Le Gal, S. Benhamou


  • Impact of a positive family history on diagnosis, management, and survival of breast cancer: different effects across socio-economic groups

    by H. M. Verkooijen, E. Rapiti, G. Fioretta, V. Vinh-Hung, J. Keller, S. Benhamou, G. Vlastos, P. O. Chappuis, C. Bouchardy


  • Open Access

    Increased risk of colon cancer after external radiation therapy for prostate cancer

    by Elisabetta Rapiti, Gerald Fioretta, Helena M. Verkooijen, Roberto Zanetti, Franz Schmidlin, Hyma Shubert, Arnaud Merglen, Raymond Miralbell, Christine Bouchardy

    Radiotherapy can induce second cancers. Controversies still exist regarding the risk of second malignancies after irradiation for prostate cancer. We evaluated the risk of developing colon and rectum cancers after prostate cancer in irradiated and nonirradiated patients. Using data from the population‐based Geneva cancer registry, we included in the study all men with prostate cancer diagnosed between 1980 and 1998 who survived at least 5 years after diagnosis. Of the 1,134 patients, 264 were treated with external radiotherapy. Patients were followed for occurrence of colorectal cancer up to 31 December, 2003. We calculated standardized incidence ratios (SIR) using incidence rates for the general population to obtain the expected cancer incidence. The cohort yielded to 3,798 person‐years. At the end of follow‐up 19 patients had developed a colorectal cancer. Among irradiated patients the SIR for colorectal cancer was 3.4 (95% confidence intervals [CI] 1.7–6.0). Compared to the general population, the risk was significantly higher for colon cancer (SIR = 4.0, 95% CI: 1.8–7.6), but not for rectal cancer (SIR = 2.0, 95% CI: 0.2–7.2). The risk of colon cancer was increased in the period of 5–9 years after diagnosis (SIR = 4.7, 95% CI: 2.0–9.2). The overall SIR of secondary cancer in patients treated with radiotherapy was 1.35 (p = 0.056). Nonirradiated patients did not have any increased risk of rectal or colon cancer. This study shows a significant increase of colon but not rectum cancer after radiotherapy for prostate cancer. The risk of second cancer after irradiation, although probably small, needs nevertheless to be carefully monitored.


  • Important excess of cardiovascular mortality among breast cancer patients irradiated for inner quadrant tumors

    by C. Bouchardy, E. Rapiti, M. Usel, S. Balmer-Majno, G. Vlastos, I. Neyroud-Caspar, H. Verkooijen, V. Vinh-Hung

    584 Background: Radiation therapy of left breast has been associated with higher cardiovascular (CV) mortality due to higher cardiotoxicity. Because tumor location can also influence heart exposure, it could influence CV mortality linked to radiotherapy. This study aims to assess CV mortality in irradiated patients according to breast cancer laterality and location. Methods: From a population-based cancer registry, we identified all women who had been irradiated for a first primary node-negative breast cancer between 1980 and 2004. We compared CV mortality between patients with cancer in the inner quadrants (n=393) versus outer quadrant (n=852) by log-rank test and by Cox regression accounting for the main prognostic factors. For all patients who die from CV, we collected and compared data on radiotherapy type and dose according to quadrant and laterality by chi-square of heterogeneity. Results: The mean follow-up was 7.7 years. Out of 1,245 patients, 28 died because of CV disease. Patients with inner tumor had a more than doubled risk for CV mortality compared with patients with outer tumor (multi-adjusted Hazard Ratio: 2.3, 95%CI: 1.1–5.1, p=0.034). Patients with breast-conserving therapy for inner cancer who die from CV received higher dose to the breast (p=0.032) but similar internal mammary chain irradiation than those with outer quadrant. Breast laterality had no effect on CV mortality. Conclusions: This study reports a strong excess of CV mortality among patients irradiated for inner breast cancer probably linked to site of the boost and higher radiation exposure of the heart. No significant financial relationships to disclose.

  • Effect of adjuvant radiation therapy on mortality according to primary tumor location in women with node-positive breast cancer: Is there a need to irradiate the internal mammary nodes?

    by V. Vinh-Hung, P. Truong, W. J. Janni, N. P. Nguyen, G. Vlastos, G. Cserni, M. E. Royce, W. A. Woodward, D. Promish, G. Storme, et al.

    545 Background: This analysis evaluates the prognostic significance of primary tumor location and examines the question of whether the effect of adjuvant radiation therapy (RT) on survival varies according to tumor location in women with node-positive breast cancer. Methods: Data were abstracted from the Surveillance, Epidemiology, and End Results database for 24,410 women aged 25- 95 years, diagnosed between 1988–1997 with nonmetastatic T1-T2 axillary node-positive primary breast carcinoma. Subgroup analyses were performed using interactions within proportional hazards models in which the event was defined as death from any cause. Prognostic variables were selected using the Akaike Information Criteria. The joint significances of subgroups were evaluated with the Wald test. Results: The median follow-up time was 10 years. In joint models, statistically significant interactions were found between tumor location, nodal involvement, type of surgery, and RT use. A factorial presentation of these interactions showed a consistent 13% proportional reduction of mortality in all subgroups (Table). The sole exception was in women with medial tumors with ≥4 positive nodes treated with mastectomy. In this subgroup, the use of RT was associated with a 16% proportional increase in mortality. Conclusions: Medial tumor location is a significant adverse prognostic factor that should be considered in treatment decision making for women with node-positive breast cancer. Improved survival was observed with RT use in all subgroups, except in women with medial tumors and ≥4 positive nodes treated with postmastectomy RT. These findings generate the hypothesis that the favorable effect of RT may have been offset by excess toxicities in the latter subgroup with the use of large fields to encompass the internal mammary nodes. Overall Mortality Hazard Ratio (HR) with or without Radiation (RT), by Number of Nodes, Surgery, Tumor Location Overall Mortality Hazard Ratio (HR) with or without Radiation (RT), by Number of Nodes, Surgery, Tumor Location No. of positive nodes Surgery Tumor quadrant RT=no HR (95% CI) RT=yes HR (95% CI) Relative mortality reduction with RT 1–3 BCS Outer 1 (=reference) 0.87 (0.82–0.92) 13% 1-3 BCS Inner 1.35 (1.20–1.52) 1.18 (1.12–1.23) 13% 1–3 Mastectomy Outer 1.09 (1.03–1.16) 0.95 (0.94–0.96) 13% 1–3 Mastectomy Inner 1.26 (1.16–1.37) 1.10 (1.07–1.12) 13% 4+ BCS Outer 1.13 (1.07–1.20) 0.99 (0.98–0.99) 13% 4+ BCS Inner 1.53 (1.34–1.75) 1.33 (1.24–1.43) 13% 4+ Mastectomy Outer 1.24 (1.14–1.34) 1.08 (1.06–1.09) 13% 4+ Mastectomy Inner 1.25 (1.17–1.34) 1.45 (1.34–1.56) -16% HRs adjusted by registry, year, race, marital, histo, grade, receptors, age, tumor size, nodal ratio No significant financial relationships to disclose.

  • Increased risk of second cancer among patients with ovarian borderline tumors

    by Christine Bouchardy, Sarah Fernandez, Arnaud Merglen, Massimo Usel, Gérald Fioretta, Elisabetta Rapiti, Hyma Schubert, Marie-Françoise Pelte, Pierre O. Chappuis, Georges Vlastos


    • 1 January 2008
      • Vol. 29  (1) , 57-60

    Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas.

    by P Petignat, M Usel, P Gauthier, Y Popowski, M F Pelte, C Bouchardy, H M Verkooijen

    Our aim was to compare the survival between patients with clear cell carcinoma (CC) and patients with endometrioid carcinoma (EC). Through the population-based Geneva Cancer Registry, we identified 1,380 resident women diagnosed with uterine cancer between 1970 and 2000. We excluded those with papillary serous endometrial carcinoma and uterine sarcomas. We categorized patients as CC (n = 32, 2.8%) or EC (n = 1,145, 97.2%). Uterine cancer-specific survival rates were calculated by Kaplan-Meier analysis. We used Cox proportional hazards analysis to compare uterine cancer mortality risks between groups, and adjusted these risks for other prognostic factors. CC patients presented with a more advanced stage at diagnosis than EC patients (p = 0.002). Compared to women with EC, women with CC had a significantly greater risk of dying from their disease (hazard ratio [HR] 2.9, 95% confidence interval (95% CI) 1.7-4.9). After adjustment for age, stage and adjuvant chemotherapy, the risk of dying from uterine cancer was still significantly higher for CC patients (HR 2.0, 95% CI 1.2-3.4). By univariate analysis, the risk of dying of endometrial cancer was not significantly higher in CC patients than in patients with poorly-differentiated EC (HR 1.3, 95% CI 0.7-2.3). This population-based investigation shows that patients with CC have a poorer outcome than those with EC. Studies to determine the role of adjuvant treatment in CC patients are needed.


  • Open Access

    Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: Results from a population‐based study

    by Helena M. Verkooijen, Gerald Fioretta, Elisabetta Rapiti, Georges Vlastos, Isabelle Neyroud‐Caspar, Pierre O. Chappuis, Christine Bouchardy

    We evaluated the impact of a family history of breast/ovarian cancer on the risk of secondary leukemia following breast cancer. At the Geneva cancer registry, we identified 4,397 patients diagnosed with invasive breast cancer between 1990 and 2004. Patients were followed up for leukemia until the end of 2005. Family history was categorized as positive in patients with ≥1 first‐ or second‐degree relative with breast/ovarian cancer. We compared leukemia rates in patients with positive and negative family histories with those expected in the general population, generating standardized incidence ratios (SIRs). With Cox regression analysis, we calculated adjusted risks of secondary leukemia in patients with familial risks compared to those without it. Breast cancer patients had a significantly increased risk of secondary acute leukemia (SIR 3.2, 95% CI: 1.2–6.9) but not of chronic leukemia (SIR 1.6, 95% CI: 0.6–3.5). Among patients with a positive family history (n = 1.125, 25.6%), the SIRs were 5.7 (95% CI: 1.2–16.6) for acute and 5.2 (95% CI: 1.4–13.3) for chronic leukemia. Among breast cancer patients, family history was independently associated with leukemia [adjusted hazard ratio (HRadj) of 3.2, 95% CI: 1.1–9.2, among patient with vs. without family history]. The effect of family history was stronger for chronic leukemia (HRadj: 11.6, 95% CI 1.3–104.7) than for acute leukemia (HRadj 1.6, 95% CI: 0.4–6.6). Breast cancer patients with a family history of breast/ovarian have an increased risk of secondary leukemia, both compared to the general population as well as to breast cancer patients without family histories. This excess risk is largely due to the increased risk of secondary chronic leukemia.